Acamprosate in the Treatment of Binge-Eating Disorder

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
Binge Eating Disorder
Interventions
DRUG

acamprosate

999 mg/day - 2997 mg/day, oral

OTHER

placebo

oral, placebo

Trial Locations (1)

45040

Lindner Center of HOPE, Mason

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Forest Laboratories

INDUSTRY

collaborator

University of Cincinnati

OTHER

lead

Lindner Center of HOPE

OTHER